Fulcrum Therapeutics (FULC) PT Raised to $20 at Stifel

Stifel analyst Dae Gon Ha raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $20.00 (from $18.00) while maintaining a Buy rating.

The analyst commented, "We reiterate our Buy rating on FULC following 1Q21 update. On the call, management reiterated upcoming data catalysts of late-June (Ph.2b ReDUX4 data in facioscapulohumeral muscular dystrophy [FSHD]) and mid-2021 (Ph.1 healthy volunteer data for FTX-6058). Additionally, the company continues to leverage its proprietary product engine, FulcrumSeek, and plans to advance 2 INDs over the next 24 months. We are updating our model and increasing our TP to $20 (from $18 previously)."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• New Street Research Upgrades Micron Technology (MU) to Buy